Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 171 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: SCRI Development Innovations, LLC Clear all
Completed Phase 1Phase 2 Interventional Results available

CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas

NCT00540579
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pomalidomide, Gemcitabine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Aurora, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 17, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer

NCT01749956
View directory record Official record
Conditions
Rectal Cancer
Interventions
Radiation, Aflibercept, Surgery, FOLFOX6
Radiation · Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
11
States / cities
Fort Myers, Florida • Pensacola, Florida • St. Petersburg, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 17, 2026, 10:46 AM EDT
Completed No phase listed Observational

Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma

NCT00876382
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Not listed
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Jonesboro, Arkansas • St. Petersburg, Florida • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 17, 2026, 10:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

NCT01611857
View directory record Official record
Conditions
Malignant Solid Tumour, Gastroesophageal Cancer
Interventions
Tivantinib, FOLFOX
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
New Haven, Connecticut • Fort Myers, Florida • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 17, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

NCT00193271
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Estramustine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Oct 17, 2026, 10:46 AM EDT
Completed Phase 3 Interventional Results available

A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer

NCT00789581
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Ixabepilone (Ixempra), Paclitaxel (Taxol)
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
69
States / cities
Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 10:46 AM EDT
Completed Phase 1 Interventional

Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors

NCT01544322
View directory record Official record
Conditions
Solid Tumors
Interventions
ME-344
Drug
Lead sponsor
MEI Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 17, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer

NCT00193167
View directory record Official record
Conditions
Colon Cancer
Interventions
Topotecan
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Oct 17, 2026, 10:46 AM EDT
Recruiting Phase 2 Interventional

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

NCT05972135
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Tucson, Arizona • Denver, Colorado • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 17, 2026, 10:46 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

NCT02100007
View directory record Official record
Conditions
Solid Tumors
Interventions
ME-344, Topotecan
Drug
Lead sponsor
MEI Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Scottsdale, Arizona • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 17, 2026, 10:46 AM EDT
Completed No phase listed Observational

A Retrospective Cohort Study of Infusion Reactions Due to Vectibix

NCT01156090
View directory record Official record
Conditions
Infusion Reaction
Interventions
Not listed
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
Not listed
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
Jonesboro, Arkansas • Augusta, Georgia • Gainesville, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2015 · Synced Oct 17, 2026, 10:46 AM EDT
Withdrawn Phase 2 Interventional

A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease

NCT01028313
View directory record Official record
Conditions
Chronic Graft-Versus-Host Disease
Interventions
LBH589, Methylprednisolone
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 17, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

NCT04699630
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer
Interventions
U3-1402
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Springdale, Arkansas • Duarte, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 17, 2026, 10:46 AM EDT
Not listed Not applicable Interventional

Rib Fixation for Clinically Severe Rib Fractures From Trauma

NCT02595593
View directory record Official record
Conditions
Rib Fracture, Flail Chest
Interventions
Rib Fixation System
Device
Lead sponsor
Darwin Ang
Other
Eligibility
18 Years to 90 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
10
States / cities
Fort Walton Beach, Florida • Ft. Pierce, Florida • Kissimmee, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 17, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer

NCT00297596
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab, Oxaliplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
7
States / cities
Bowling Green, Kentucky • Alexandria, Louisiana • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 17, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

NCT01076504
View directory record Official record
Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
Amrubicin, Carboplatin, Pegfilgrastim
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
20
States / cities
Jonesboro, Arkansas • Fort Myers, Florida • Lakeland, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 17, 2026, 10:46 AM EDT
Active, not recruiting Phase 2 Interventional

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

NCT06773910
View directory record Official record
Conditions
Limited Stage Small Cell Lung Cancer
Interventions
BMS-986489, Durvalumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
34
States / cities
Daphne, Alabama • Santa Barbara, California • Fort Myers, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer

NCT00308529
View directory record Official record
Conditions
Carcinoma, Small Cell Lung, Lung Cancer
Interventions
irinotecan, carboplatin, bevacizumab, Radiation Therapy
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Fort Myers, Florida • Cincinnati, Ohio • Chattanooga, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Oct 17, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

NCT03977467
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Solid Tumor
Interventions
Atezolizumab, Standard of Care Chemotherapy, Tiragolumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Tallahassee, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 17, 2026, 10:46 AM EDT
Terminated Phase 2 Interventional Results available

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

NCT01934894
View directory record Official record
Conditions
Metastatic Breast Cancer With Intracranial Metastases
Interventions
cabazitaxel, lapatinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 10:46 AM EDT
Terminated Phase 2 Interventional Results available

A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.

NCT01928693
View directory record Official record
Conditions
Corneal Ulcers
Interventions
Besivance 0.6% Ophthalmic Suspension, Zymaxid 0.5% Ophthalmic Solution, Vigamox 0.5% Ophthalmic Solution
Drug
Lead sponsor
Cornea Consultants Of Nashville
Other
Eligibility
18 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 17, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer

NCT00193453
View directory record Official record
Conditions
Lung Cancer
Interventions
Gemcitabine, Docetaxel, Cetuximab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
10
States / cities
Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2012 · Synced Oct 17, 2026, 10:46 AM EDT
Completed No phase listed Observational

Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting

NCT00877045
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Not listed
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Fort Myers, Florida • Atlanta, Georgia • Chattanooga, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2010 · Synced Oct 17, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer

NCT00193076
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Carboplatin, Trastuzumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Oct 17, 2026, 10:46 AM EDT